Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission, discusses the role of MACPAC in sharing data with policy makers.
Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission (MACPAC), discusses the role of MACPAC in sharing data with policy makers.
Transcript
What role should data play in shaping healthcare policy?
Ideally, data should be used to inform policy decisions and evaluation of policy. That’s core to what MACPAC does. We try to provide evidence and data to inform policy decisions on Medicaid and CHIP that are being by congress, by the Department of Health and Human Services, and by the states. There are sometimes moments where the right data don’t exist but data always help us better understand who the program is serving, what it is spending, where gaps are and whether policies are having their intended results.
How can organizations like MACPAC work to share data and evidence with policy makers in a way that can be readily understood in the current environment?
One of the signature products from MACPAC is our data compilation called MACSTATS. When MACPAC got started, we realized that data on Medicaid and CHIP were scattered on numerous sources in different federal agencies, buried in federal data sources, so we created this data resource to be able to inform both federal and state decision makers. It’s something that’s on our website, has information on trends and enrollment and spending, as well as basic information about the program such as eligibility levels for groups across states.
One thing that I find really somewhat amusing, but also gratifying, about MACSTATS is in this age of electronic information, we of course have it online, we have it in PDFs, and we have it in Excel so people can access it at any time. But we also still publish a print book and we know that’s really important to people. People on the Hill keep that book on their desk to thumb through to find out information about their state in different aspects of the program.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More